Medicare AdvantageCoverageMedium impact
MA08.083k, Leuprolide Acetate (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®)
Independence Blue Cross·Oncology, Endocrinology, Urology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.083k for Leuprolide Acetate (Camcevi, Eligard, Fensolvi, Lupron Depot) has been updated with changes effective October 1, 2025. This affects coverage or requirements for these hormone therapy medications commonly used in oncology and endocrinology practices.
Action Required
By October 1, 2025: Review updated policy MA08.083k for Leuprolide Acetate products (Camcevi, Eligard, Fensolvi, Lupron Depot) at the provided URL. Billing team must verify current prior authorization requirements, coverage criteria, and documentation needs for Medicare Advantage patients receiving these medications. Update billing system and provider workflows accordingly to ensure compliance with new policy requirements.